For instance, Ras/Raf/Mek signalling has come to the fore with the finding that up to 50% of melanomas have a BRAF mutation and up to 30% have a NRAS mutation [23] [24, 25], with resulting inhibitors targeting BRAF specifically [26] and MEK signalling in general [27]. The gene discussed is BRAF; the disease is melanoma.